Aptorum Group Ltd - Class A
Research Aptorum Group Ltd - Class A (APM) on Bullrun: market cap USD 68.49M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 68.49M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 1.36M
- Free cash flow-USD 1.84M
Valuation Snapshot
latest market cap is USD 68.49M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.36M | -USD 1.84M | n/a | -0.19 | USD 3.45M | USD 3.44M | USD 23.12M |
| FY2024 | USD 0 | -USD 4.27M | -USD 1.19M | n/a | -0.78 | USD 874.24K | USD 3.35M | USD 21.13M |
| FY2023 | USD 431.38K | -USD 2.82M | -USD 7.73M | 2.4% | -0.62 | USD 2.01M | USD 3.28M | USD 24.85M |
| FY2022 | USD 1.30M | -USD 9.80M | -USD 12.51M | 6.2% | -2.75 | USD 5.01M | USD 129.85K | USD 15.71M |
| FY2021 | USD 1.54M | -USD 25.05M | -USD 14.78M | 5.3% | -7.15 | USD 8.26M | USD 296.23K | USD 23.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-27 | USD 68.49M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.63M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 15.70M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 12.70M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 19.64M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 53.46M | n/a | n/a | n/a |
About Aptorum Group Ltd - Class A
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aptorum Group Ltd - Class A's market cap?
Aptorum Group Ltd - Class A's market capitalization is USD 68.49M.
What does Aptorum Group Ltd - Class A do?
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.